<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331900</url>
  </required_header>
  <id_info>
    <org_study_id>COR388-001</org_study_id>
    <nct_id>NCT03331900</nct_id>
  </id_info>
  <brief_title>Study of COR388 HCl in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Single Ascending Dose Study of COR388 HCl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortexyme Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortexyme Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, dose escalation, first-in-human
      trial of the safety and tolerability of COR388 HCl in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the first occurrence of the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>72 Hours</time_frame>
    <description>Assessment of the incidence and severity of treatment-emergent adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in chemistry lab measures (Sodium [Na], Blood Urea Nitrogen [BUN], Calcium [Ca], Total bilirubin).</measure>
    <time_frame>72 hours</time_frame>
    <description>Assessment of changes in serum chemistry measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hematology lab measures (RBC, Hgb, Hct).</measure>
    <time_frame>72 hours</time_frame>
    <description>Assessment of changes in hematology measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinalysis lab parameters (pH, specific gravity, glucose).</measure>
    <time_frame>72 hours</time_frame>
    <description>Assessment of changes in urinalysis parameters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COR388 TBD mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COR388</intervention_name>
    <description>Administered as oral capsule</description>
    <arm_group_label>COR388 TBD mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          1. Males of reproductive potential must agree to use double-barrier contraceptive
             measures or avoid intercourse from Day -1 through 28 days after the dose of study
             drug;

          2. Females of child-bearing potential must be non-lactating, have negative serum
             pregnancy test results at screening visit and Day 1; agree to use double-barrier
             contraceptive measures or avoid intercourse from Day -10 through 28 days after the
             dose of study drug;

          3. Body mass index (BMI) ≥19 to ≤32 kg/m2;

          4. Good health as determined by the absence of clinically significant deviation from
             normal, by medical history, physical examination, laboratory reports, and 12-lead
             electrocardiogram (ECG) prior to enrollment;

          5. Non-smoker and non-tobacco user for a minimum of 3 months prior to screening and for
             the duration of the study;

          6. Able to understand and willing to comply with all study requirements, and follow the
             study medication regimen.

        Major Exclusion Criteria:

          1. History or current evidence of cardiac, hepatic, renal, pulmonary, endocrine,
             neurologic, gastrointestinal, hematologic, oncologic, infectious, or psychiatric
             disease as determined by screening history, physical examination, laboratory reports,
             or 12-lead ECG;

          2. Need for any concomitant medication (with the exception of hormonal contraceptives as
             allowed for females of child-bearing potential);

          3. Use of any prescription drug within 14 days prior to the first dose of the study (with
             the exception of hormonal contraceptives for females of childbearing potential);

          4. Use of any non-prescription drug and/or herbal supplements within 7 days prior to the
             first dose of the study;

          5. History of significant allergic reaction to any drug;

          6. Participation in another investigational new drug research study within the 30 days
             prior to the first dose of the study;

          7. History of alcohol or drug abuse or dependence within 12 months of screening as
             determined by the Investigator;

          8. Positive urine screen for prohibited drugs or positive alcohol screen on Day -1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

